Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 30

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 30
---
 Issuance                                                                
 of Series A Preferred Warrants                                          |     |                 |      - |     |        |         - |     |          |     - |   |     |        | - |     |            |  2,000,000 |   |     |              | (2,000,000 | ) |     |             | -           |   |     |       |           - |   |
| Issuance                                                                
 of common shares to Keystone Capital LLC for equity line of credit      |     |                 |      - |     |        |         - |     |          |    59 |   |     |        | - |     |            |    633,345 |   |     |              | -          |   |     |             | -           |   |     |       |     633,345 |   |
| Opening                                                                 
 Equity at February 14, 2024 (Successor)                                 |     |                 | 10,089 |     | $      | 8,937,852 |     |          | 7,266 |   |     | $      | 1 |     | $          | 53,899,885 |   |     | $            | (2,000,000 | ) |     | $           | (63,185,641 | ) |     | $     |  (2,347,903 | ) |

NOTE 4 – NET LOSS PER SHARE OF COMMON STOCK

The accounting standards require the presentation of both basic and diluted earnings per share on the face of the statements of operations. The Company’s basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding for the period. If there are dilutive securities, diluted income per share is computed by including common stock equivalents which includes shares issuable upon the exercise of stock options into shares of common stock, exercise of preferred warrants into shares of preferred stock, and conversion of preferred stock into shares of common stock, net of any shares assumed to have been purchased with the proceeds, using the treasury stock method. In periods for which the Company reports a net loss, the common stock equivalents are not included, as they would be anti-dilutive.

<div align='center'>13</div>

The following table summarizes the number of shares of Common Stock issuable upon conversion or exercise, as applicable, of convertible securities, stock options, and warrants that were not included in the calculation